QURE
uniQure N.V.
Halal Rating :
Last Price
$14.20
Last updated:
Market Cap
-
7D Change
2.97%
1 Year Change
149.12%
Company Overview
Industries
Exchange
Next Earnings Date
uniQure N.V. is a gene therapy company focused on developing treatments for patients suffering from genetic and other severe diseases. The company specializes in developing adeno-associated virus (AAV)-based gene therapies. Their pipeline includes treatments for hemophilia B, Huntington's disease, and other rare genetic conditions.
The company leverages its proprietary technology platform to develop innovative gene therapies that aim to restore or provide genetic functions to treat severe genetic diseases and rare disorders.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $2.29m | $59.13m | - | $16.61m | 0.00% | 28.09% |
| June 30, 2024 | $11.13m | $71.29m | - | $16.16m | 0.00% | 22.66% |
| March 31, 2024 | $8.48m | $78.81m | - | $16.1m | 0.00% | 20.43% |
Company Impact
Help us evaluate uniQure N.V.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.